Previous 10 | Next 10 |
CHARLOTTESVILLE, Va. and CARMEL, Ind., May 11, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company wil...
The following slide deck was published by Acumen Pharmaceuticals, Inc. in conjunction with this event. For further details see: Acumen Pharmaceuticals (ABOS) Investor Presentation - Slideshow
CHARLOTTESVILLE, Va. and CARMEL, Ind., April 27, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that Frontie...
Image source: The Motley Fool. Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Q4 2021 Earnings Call Mar 28, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Acumen Pharmaceuticals, Inc. (ABOS) Q4 2021 Earnings Call Tran...
The following slide deck was published by Acumen Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Acumen Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2021 Earnings Conference Call March 28, 2022 4:30 AM ET Company Participants John Woolford - IR, Westwicke Daniel O'Connell - President & CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participan...
Acumen Pharmaceuticals press release (NASDAQ:ABOS): FY GAAP EPS of -$5.02 misses by $1.56. FY Cash and cash equivalents of $122.16M For further details see: Acumen Pharmaceuticals GAAP EPS of -$5.02 misses by $1.56
Acumen is progressing ACU193, the first monoclonal antibody designed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical testing Currently enrolling INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-as...
CHARLOTTESVILLE, Va. and CARMEL, Ind., March 16, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company w...
Acumen Pharmaceuticals (NASDAQ:ABOS): Q3 GAAP EPS of -$0.10 beats by $0.07. Cash equivalents and marketable securities of $199.96M Press Release For further details see: Acumen Pharmaceuticals EPS beats by $0.07
News, Short Squeeze, Breakout and More Instantly...
Acumen Pharmaceuticals Inc. Company Name:
ABOS Stock Symbol:
NASDAQ Market:
Acumen Pharmaceuticals Inc. Website:
NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) in the brain for the treatment of Alzheimer’s disease (AD),&...
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...
NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...